
Cardiology
OPTIMA-AF supports stopping the P2Y12 inhibitor after 1 month in selected patients with atrial fibrillation undergoing PCI, reducing important bleeding without an apparent loss of thromboembolic protection.
Egbavwe Pela · 6 min read

Endocrinology & Metabolism
Tirzepatide reduced apnea severity and body weight in adults with obesity and moderate-to-severe obstructive sleep apnea, supporting FDA approval with or without ongoing positive airway pressure therapy.
Egbavwe Pela · 7 min read

Innovation & Devices
For people living with ulcerative colitis (UC), a newly available oral therapy, carotegrast methyl (CGM), offers a vital
Egbavwe Pela · 7 min read